Gyros launches Gyrolab Bioaffy at Drug Discovery and Technology, Boston

07-Aug-2003

Gyros will launch Gyrolab Bioaffy during the upcoming Drug Discovery and Technology meeting, starting August 11 at the Hynes Convention Center, Boston, USA.

Gyrolab Bioaffy, a CD microlaboratory, together with an updated Gyrolab Workstation with laser-induced fluorescence detection, allows scientists to run established sandwich-based immunoassays for protein quantification at nanoliter scale.

Proteins can be assayed in a format optimized for working with small volumes and many samples. Nanoliter scale procedures will give a major reduction in sample and reagent consumption per data point. Time-consuming and costly investigations caused by limited availability of sample, such as biomarker profiling in small animal models, can be reduced to days rather than weeks with more proteins being assayed in a single sample.

Quantification of cytokines and latest results from this new CD microlaboratory will be presented at a technology workshop in Room 310, Hynes Convention Center, at 4.30 pm on Tuesday, August 12.

The launch of Gyrolab Bioaffy confirms the company’s earlier claim that Gyros technology platform allows development of multi-application instruments. Both Gyrolab Bioaffy and Gyrolab MALDI CD microlaboratories can be run on the same workstation.


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.